Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 7, 2026

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation
06:13

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Published on: June 20, 2018

Sinus implants for chronic rhinosinusitis: technology evaluation.

Jivianne T Lee1, Joseph K Han

  • 1Department of Otolaryngology & Head and Neck Surgery , David Geffen School of Medicine at UCLA , USA.

Expert Opinion on Drug Delivery
|October 4, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?

International forum of allergy & rhinology·2026
Same author

Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysis.

Advances in therapy·2026
Same author

Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.

Human vaccines & immunotherapeutics·2026
Same author

Traffic and Industrial Pollutants and Chronic Rhinosinusitis.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Reply to: S. N. Katkuri et al. and H. Liu et al. on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

International forum of allergy & rhinology·2026
Same author

Minimal Clinically Important Difference of the Sinonasal Outcome Test in Sinonasal Malignancy.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Dry powder inhaler selection in COPD: integrating device design, formulation performance, and patient inspiratory capability.

Expert opinion on drug delivery·2026
Same journal

Letter to the Editor: 'saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'.

Expert opinion on drug delivery·2026
Same journal

Response to letter to the editor: 'Saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'.

Expert opinion on drug delivery·2026
Same journal

Mechanism-guided metal complex therapeutics for biofilm-driven wound infections and transdermal delivery.

Expert opinion on drug delivery·2026
Same journal

Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologies.

Expert opinion on drug delivery·2026
Same journal

Drug penetration in solid tumors: influence of drug size and capillary architecture.

Expert opinion on drug delivery·2026
See all related articles

Sinus implants offer a novel way to deliver corticosteroids directly to the sinonasal mucosa after endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS). This method improves wound healing and reduces the need for further medical or surgical interventions.

Area of Science:

  • Otolaryngology
  • Drug Delivery Systems
  • Biomaterials

Background:

  • Endoscopic sinus surgery (ESS) is a key treatment for chronic rhinosinusitis (CRS).
  • Post-surgical complications like synechiae, polyps, and edema can impact long-term outcomes.
  • Current corticosteroid delivery methods have limitations in efficacy and systemic side effects.

Purpose of the Study:

  • To introduce sinus implants as a novel drug delivery vehicle for CRS.
  • To detail the technology behind sinus implants for sustained corticosteroid release.
  • To explore the potential of sinus implants in managing post-ESS inflammation and improving outcomes.

Main Methods:

  • Review of bioengineering principles of sinus implants.
  • Assessment of drug delivery mechanisms, degradation, and resorption.

More Related Videos

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
07:30

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction

Published on: October 13, 2017

Related Experiment Videos

Last Updated: May 7, 2026

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation
06:13

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Published on: June 20, 2018

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
07:30

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction

Published on: October 13, 2017

  • Evaluation of existing animal and clinical study findings.
  • Comparison with alternative drug delivery devices.

    • Main Results:

    • Sinus implants provide sustained, controlled topical corticosteroid delivery.
    • Demonstrated enhancement of wound healing in the sinonasal mucosa.
    • Reduced need for secondary postoperative medical and surgical treatments.

    Conclusions:

    • Sinus implants represent a revolutionary approach to localized drug delivery in CRS.
    • This technology improves surgical outcomes and patient quality of life.
    • Future applications may extend to clinical management of inflammatory exacerbations and recurrent disease.